Ondine Biomedical Joins CAN Health Network to Advance its Innovation in Infection Prevention Across Canada Membership provides strategic support, insights and connections as Ondine works to scale its infection prevention technology. Ondine Biomedical Inc. (LON: OBI) is pleased to announce its membership with the CAN Health Network — a [...]

First UK Deployment at Mid Yorkshire Teaching NHS Trust reduces SSI rates by 71% with Steriwave Nasal Photodisinfection Ondine Biomedical Inc. (LON: OBI) reports that results from the first NHS deployment of Steriwave® nasal decolonization technology at Mid Yorkshire Teaching NHS Trust (Mid Yorks) have demonstrated a substantial reduction in [...]

First patients recruited into Steriwave ICU pilot study and related Issue of Shares Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New [...]

Quebec’s Sherbrooke University Hospital Cuts surgical site infections in patients undergoing spine surgery by 78% Results demonstrated that patients treated with Steriwave nasal photodisinfection (aPDT) experienced >78% fewer SSIs than untreated patients. Hospital length of stay also decreased by 30% in the Steriwave treated patients. La Malbaie, Quebec – [...]

Innovative light-activated antimicrobial treatment has potential to become first FDA-approved nasal decolonization treatment for prevention of surgical site infections Ondine’s light-activated antimicrobial therapy for nasal decolonization would apply to more than 35 million major surgical procedures in the USA annually. Surgical site infections (“SSIs”) account for 20% of all [...]

This Announcement uses a US$:£ exchange rate of 1 : 0.808210 as at 16:30 (GMT) on 2 January 2025. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company developing light-activated antimicrobial treatments, is pleased to announce that hInsight-NX, LLC, a subsidiary of HCA Healthcare, Inc., a leading healthcare [...]

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, has enrolled and treated the first patient in the Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections (‘LANTERN’) Phase 3 clinical trial. The trial, involving approximately 5,000 patients in 14 hospitals, is evaluating Ondine’s non-antibiotic nasal photodisinfection technology, branded [...]

Ondine announced today the imminent start of the LANTERN Phase 3 clinical trial of its novel nasal photodisinfection technology, branded as Steriwave® outside the US. The U.S. Food and Drug Administration (FDA) has raised no objections to starting the study during its statutory 30-day review period of the Company's [...]